Loading
A phase 2 trial of CR-001 run by Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., not yet recruiting.
A Phase II Study of SKB264 + SKB118 in Nsq-NSCLC After EGFR-TKI Failure is a phase 2 interventional study registered as NCT07854509 by Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., with 110 participants planned, started 2026-10-15. Conditions recorded: Non-Squamous Non-Small Cell Lung Cancer. Interventions recorded: SKB264+SKB118.
Shares CR-001, Sichuan Kelun-Biotech, Non-small-cell lung cancer and the tag pipeline.
Shares CR-001, Crescent Biopharma and the tag pipeline.
Shares CR-001, Sichuan Kelun-Biotech and the tag pipeline.
Shares Crescent Biopharma, Non-small-cell lung cancer and the tag pipeline.
Shares Sichuan Kelun-Biotech and the tag pipeline.
Shares Sichuan Kelun-Biotech and the tag pipeline.
Shares Sichuan Kelun-Biotech and the tag pipeline.
Shares Sichuan Kelun-Biotech and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/